Breast cancer (invasive) · line 3 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | None |
| ID | IND-BREAST-HR-POS-3L-POST-CDK46I-POST-AKT |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | DIS-BREAST |
| Sources | SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. 3L+ salvage pathway after CDK4/6i + AI 1L exhaustion AND PI3K/AKT-targeted 2L. Multiple competing 3L+ options; treatment selection requires biomarker re-evaluation + access assessment. Missing entity flag: dedicated REG-EVEROLIMUS-EXEMESTANE + REG-ELACESTRANT — author in PROD-2.
Used By
Indication
IND-BREAST-HR-POS-MAINT-CDK46I- IND-BREAST-HR-POS-MAINT-CDK46I